PranaX, a Houston, USA-based biotech specializing in exosome-based regenerative therapies, has appointed Phillip Maderia as ...

RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the ...

Say goodbye to hair loss with exosome therapy Explore how exosomes work to stimulate hair follicles and enhance hair density ...

Temporomandibular joint osteoarthritis (TMJOA) is a debilitating condition that causes severe joint pain, restricted mobility ...

This new study explores the potential of strontium (Sr)-enhanced exosomes, derived from synovial mesenchymal stem cells (SMSCs), as a promising therapeutic approach for temporomandibular joint ...

Top dermatologists share skin and hair care secrets for women, emphasizing exosome therapy, collagen banking, and sunscreen ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...

Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated ...